Skip to main content
Erschienen in: Digestive Diseases and Sciences 12/2010

01.12.2010 | Original Article

Patient and Physician Satisfaction with Proton Pump Inhibitors (PPIs): Are There Opportunities for Improvement?

verfasst von: William D. Chey, Reema R. Mody, Esin Izat

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Few studies have explored the satisfaction with proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD).

Aim

The aim of this study was to assess patient and physician satisfaction with currently prescribed PPIs for patients with GERD.

Methods

Separate online surveys were completed by 1,002 physicians and 1,013 GERD patients. Physician surveys examined satisfaction, symptom relief, long-term therapy, side-effects, breakthrough symptoms, and use of supplemental medications with PPIs. Patient surveys evaluated PPI regimen, length of therapy, satisfaction with PPI, symptom relief, use of supplemental medications, and perceptions about long-term use and side-effects.

Results

Most respondents were satisfied with PPI therapy, but 35.4% of GERD patients and 34.8% of physicians perceived patients as “somewhat satisfied” to “completely dissatisfied” with PPI therapy. Patients who were highly satisfied were more likely to indicate complete symptom relief (P < 0.001) relative to patients who were less satisfied. However, over 35% of patients on once-daily and 54% on twice-daily PPI indicated that therapy failed to completely relieve symptoms. Patients who were highly satisfied were more likely to recommend medication to patients with the same symptoms (P < 0.001) and less likely to report that the medication is too expensive (P < 0.001), worry about long-term use (P < 0.001), or add OTC medications for supplemental control (P < 0.004).

Conclusions

Approximately one-third of GERD patients reported persistent symptoms and were dissatisfied with PPI therapy.
Fußnoten
1
PCP categorization included general practitioners, family practitioners, internal medicine practitioners, and osteopathic practitioners.
 
Literatur
1.
Zurück zum Zitat Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–1511.CrossRefPubMed Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–1511.CrossRefPubMed
2.
Zurück zum Zitat Armstrong D. Systematic review: persistence and severity in gastroesophageal reflux disease. Aliment Pharmacol Ther. 2008;28:841–853.PubMed Armstrong D. Systematic review: persistence and severity in gastroesophageal reflux disease. Aliment Pharmacol Ther. 2008;28:841–853.PubMed
3.
Zurück zum Zitat Vakil N. Review article: New pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;19:1041–1049.CrossRefPubMed Vakil N. Review article: New pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;19:1041–1049.CrossRefPubMed
4.
Zurück zum Zitat Calabrese C, Fabbri A, Di Febo G. Long-term management of GERD in the elderly with pantoprazole. Clin Intery Aging. 2007;2:85–92.CrossRef Calabrese C, Fabbri A, Di Febo G. Long-term management of GERD in the elderly with pantoprazole. Clin Intery Aging. 2007;2:85–92.CrossRef
5.
6.
Zurück zum Zitat Becker V, Bajbouj M, Waller K, Schmid RM, Meining A. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors—a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther. 2007;26:1355–1360.CrossRefPubMed Becker V, Bajbouj M, Waller K, Schmid RM, Meining A. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors—a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther. 2007;26:1355–1360.CrossRefPubMed
8.
Zurück zum Zitat Liker H, Hungin P, Wiklund I. Managing gastroesophageal reflux disease in primary care: the patient perspective. J Am Board Fam Pract. 2005;18:393–400.CrossRefPubMed Liker H, Hungin P, Wiklund I. Managing gastroesophageal reflux disease in primary care: the patient perspective. J Am Board Fam Pract. 2005;18:393–400.CrossRefPubMed
9.
Zurück zum Zitat Bretagne JF, Honnohat C, Richard-Mollard B, Caekkaerts A, Barthelemys P. Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther. 2006;23:607–616.CrossRefPubMed Bretagne JF, Honnohat C, Richard-Mollard B, Caekkaerts A, Barthelemys P. Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther. 2006;23:607–616.CrossRefPubMed
10.
Zurück zum Zitat Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease—an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18:767–776.CrossRefPubMed Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease—an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18:767–776.CrossRefPubMed
11.
Zurück zum Zitat Wahlqvist P, Karlsson M, Johnson D, Carlsson J, Bolge SC, Wallander MA. Relationship between symptom load of gastro-esophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment Pharmacol Ther. 2008;27:960–970.CrossRefPubMed Wahlqvist P, Karlsson M, Johnson D, Carlsson J, Bolge SC, Wallander MA. Relationship between symptom load of gastro-esophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment Pharmacol Ther. 2008;27:960–970.CrossRefPubMed
12.
Zurück zum Zitat Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J Clin Outcomes Manag. 2000;7:29–34. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J Clin Outcomes Manag. 2000;7:29–34.
13.
Zurück zum Zitat Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2004;2:CD003245. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2004;2:CD003245.
14.
Zurück zum Zitat Robinson M, Shaw K. Proton pump inhibitor attitudes and usage: a patient survey. Pharm Ther. 2002;27:202–206. Robinson M, Shaw K. Proton pump inhibitor attitudes and usage: a patient survey. Pharm Ther. 2002;27:202–206.
15.
Zurück zum Zitat Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14:1267–1272.CrossRefPubMed Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14:1267–1272.CrossRefPubMed
16.
Zurück zum Zitat Hunt R, Yuan Y, Yaghoobi M. GERD: new strategies and new failures. J Clin Gastroenterol. 2007;41(Supp 2):S72–S80.CrossRef Hunt R, Yuan Y, Yaghoobi M. GERD: new strategies and new failures. J Clin Gastroenterol. 2007;41(Supp 2):S72–S80.CrossRef
17.
Zurück zum Zitat Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55:1398–1402.CrossRefPubMed Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55:1398–1402.CrossRefPubMed
18.
Zurück zum Zitat Rubenstein JH, Nojkov B, Korsnes S, et al. Esophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:443–452.CrossRefPubMed Rubenstein JH, Nojkov B, Korsnes S, et al. Esophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:443–452.CrossRefPubMed
19.
Zurück zum Zitat Nojkov B, Saad R, Adlis S, Shaw M, Chey WD. Predictors of response to PPI therapy in patients with GERD: the influence of co-morbid IBS and psychological disease. Aliment Pharmacol Ther. 2008;27:473–482.CrossRefPubMed Nojkov B, Saad R, Adlis S, Shaw M, Chey WD. Predictors of response to PPI therapy in patients with GERD: the influence of co-morbid IBS and psychological disease. Aliment Pharmacol Ther. 2008;27:473–482.CrossRefPubMed
Metadaten
Titel
Patient and Physician Satisfaction with Proton Pump Inhibitors (PPIs): Are There Opportunities for Improvement?
verfasst von
William D. Chey
Reema R. Mody
Esin Izat
Publikationsdatum
01.12.2010
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 12/2010
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1209-2

Weitere Artikel der Ausgabe 12/2010

Digestive Diseases and Sciences 12/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.